These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18820805)

  • 21. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advanced glycosylation end products and chronic complications of diabetes mellitus].
    Méndez JD
    Gac Med Mex; 2003; 139(1):49-55. PubMed ID: 12666409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced glycation end products and the pathogenesis of diabetic nephropathy.
    Yamagishi S; Takeuchi M; Makita Z
    Contrib Nephrol; 2001; (134):30-5. PubMed ID: 11665285
    [No Abstract]   [Full Text] [Related]  

  • 24. Advanced glycation end products and diabetic nephropathy.
    Thomas MC; Forbes JM; Cooper ME
    Am J Ther; 2005; 12(6):562-72. PubMed ID: 16280650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The vascular complications of diabetes mellitus.
    Gnudi A; Lugari R
    Acta Biomed Ateneo Parmense; 1995; 66(3-4):119-24. PubMed ID: 8578928
    [No Abstract]   [Full Text] [Related]  

  • 26. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.
    Bierhaus A; Ritz E; Nawroth PP
    Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of inflammatory and vascular endothelial dysfunction biomarkers in microvascular and macrovascular complications in type 1 diabetes.
    Wołoszyn-Durkiewicz A; Myśliwiec M
    Pediatr Endocrinol Diabetes Metab; 2019; 25(1):28-35. PubMed ID: 31343130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
    Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
    Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tannins and vascular complications of Diabetes: An update.
    Laddha AP; Kulkarni YA
    Phytomedicine; 2019 Mar; 56():229-245. PubMed ID: 30668344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Possible participation of advanced glycation endproducts and their receptor system in the development of diabetic vascular complications].
    Yamamoto Y; Sakurai S; Watanabe T; Yonekura H; Yamamoto H
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):49-55. PubMed ID: 12617038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABC of arterial and venous disease: vascular complications of diabetes.
    Donnelly R; Emslie-Smith AM; Gardner ID; Morris AD
    BMJ; 2000 Apr; 320(7241):1062-6. PubMed ID: 10764371
    [No Abstract]   [Full Text] [Related]  

  • 32. Protective role of sulphoraphane against vascular complications in diabetes.
    Yamagishi S; Matsui T
    Pharm Biol; 2016 Oct; 54(10):2329-39. PubMed ID: 26841240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced glycation: implications in tissue damage and disease.
    Gasser A; Forbes JM
    Protein Pept Lett; 2008; 15(4):385-91. PubMed ID: 18473952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced glycation end products.
    Thomas MC
    Contrib Nephrol; 2011; 170():66-74. PubMed ID: 21659759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TAGE (toxic AGEs) theory in diabetic complications.
    Sato T; Iwaki M; Shimogaito N; Wu X; Yamagishi S; Takeuchi M
    Curr Mol Med; 2006 May; 6(3):351-8. PubMed ID: 16712480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible significance of advanced glycation end products in serum in end-stage renal disease and in late complications of diabetes.
    Dolhofer-Bliesener R; Lechner B; Gerbitz KD
    Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):355-61. PubMed ID: 8704053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diabetes mellitus. Metabolic, vascular, neurologic and infectious complications].
    Guillausseau PJ; Guillausseau-Scholer C
    Soins; 1989 May; (524):8-14. PubMed ID: 2749315
    [No Abstract]   [Full Text] [Related]  

  • 38. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors.
    Vlassara H; Bucala R
    Diabetes; 1996 Jul; 45 Suppl 3():S65-6. PubMed ID: 8674896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of nonenzymatic glycation and glyco-oxidation in the development of diabetic vascular complications].
    Jakus V
    Cesk Fysiol; 2003 May; 52(2):51-65. PubMed ID: 12827898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
    Jandeleit-Dahm KA; Lassila M; Allen TJ
    Ann N Y Acad Sci; 2005 Jun; 1043():759-66. PubMed ID: 16037303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.